← Leaderboards
Mark Cayabyab
Ada Forsyth Institute, Inc.
$3,441,851
Attributed
$3,441,851
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $781.9K · FY2012–21$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$3,441,851 · 3
By mechanism
R01$2,955,621 · 1
R03$486,230 · 2
Top collaborators
No co-investigators on record.
Most similar at Ada Forsyth Institute, Inc.
Same institution · by research overlap
- Xuesong He$7,731,091
Others in their field
Top investigators on “Vector Vaccine”
- Lawrence Corey · Fred Hutchinson Cancer Center$446,547,761
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$239,426,049
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$142,420,923
- Peter B. Gilbert · Fred Hutchinson Cancer Center$124,587,333
- Louis J. Picker · Oregon Health And Science University$70,366,260
- David Heimbrook · Leidos Biomedical Research, Inc.$68,561,099
Research focus
Vector VaccineAnimalsVaccine AntigenVectorPre-ClinicalVaccine DeliveryNonhuman PrimateTransmission ProcessNeutralizing AntibodyVaccinesImmunogenicityInnovationAids/Hiv ProblemAntigensAids VaccinesHiv VaccineHiv-1RecombinantsBaseMucosal ImmunityAdenovirus VectorPathogenImmunogenicCytotoxic T-Lymphocytes
Grant awards (9)
Novel Recombinant Streptococcus mitis as an Oral Vaccine against HIV/AIDS$718,151
R01 · FY2021 · DE · contact PI
Novel Recombinant Streptococcus mitis as an Oral Vaccine against HIV/AIDS$781,892
R01 · FY2020 · DE · contact PI
Novel Recombinant Streptococcus mitis as an Oral Vaccine against HIV/AIDS$475,721
R01 · FY2019 · DE · contact PI
Novel Recombinant Streptococcus mitis as an Oral Vaccine against HIV/AIDS$470,578
R01 · FY2018 · DE · contact PI
Novel Recombinant Streptococcus mitis as an Oral Vaccine against HIV/AIDS$509,279
R01 · FY2017 · DE · contact PI
Optimized second-generation recombinant mycobacteria vaccine vectors against HIV$96,850
R03 · FY2016 · AI · contact PI
Optimized second-generation recombinant mycobacteria vaccine vectors against HIV$96,850
R03 · FY2015 · AI · contact PI
Recombinant streptococcus mitis vaccine technology against HIV and other diseases$143,280
R03 · FY2013 · DE · contact PI
Recombinant streptococcus mitis vaccine technology against HIV and other diseases$149,250
R03 · FY2012 · DE · contact PI